Similarly, Gambichler et al. evaluate the effects of PD-1 antibody blockade treatment on Treg subsets in the blood of melanoma patients, showing that the use of nivolumab or pembrolizumab leads to a rapid decrease in PD-1+ Tregs in peripheral blood, reducing the risk of melanoma-specific death [97]. This evidence concerns the gene PDCD1 and melanoma.